Genes
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
85,013 comparisons from ClinicalTrials.gov.
Most participants first33,758 with no events in either group come last2,561 to 2,580 of 85,013
| Comparison | With the outcome | Risk difference, 95% interval | Participants | Trial |
|---|---|---|---|---|
| Liberal Group vs Restrictive Group: serious adverse events | 103 of 1,493 118 of 1,490 | -1.0 points -2.9 to 0.9 | 2,983 | NCT02073162 REstrictive Versus LIbEral Fluid Therapy in Major Abdominal Surgery |
| Trivalent MRKAd5 HIV-1 Gag/Pol/Nef vs Placebo: serious adverse events | 19 of 1,484 17 of 1,495 | 0.1 points -0.7 to 1.0 | 2,979 | NCT00095576 Investigation of V520 in an HIV Vaccine Proof-of-Concept Study (V520-023) |
| Arm I:Sentinel Node Resection+Conventional Axillary Dissection vs Arm II: Sentinel Node Resection Followed by Node Examination: Morbidity - Number of Participants With Residual Shoulder Abduction Deficit | 276 of 1,449 200 of 1,519 | 5.9 points 3.2 to 8.5 | 2,968 | NCT00003830 Surgery to Remove Sentinel Lymph Nodes With or Without Removing Lymph Nodes in the Armpit in Treating Women With Breast Cancer |
| Liberal vs Restrictive: Sepsis | 129 of 1,487 157 of 1,481 | -1.9 points -4.1 to 0.2 | 2,968 | NCT01424150 REstrictive Versus LIbEral Fluid Therapy in Major Abdominal Surgery: RELIEF Study |
| Liberal vs Restrictive: Pulmonary Oedema | 32 of 1,487 20 of 1,481 | 0.8 points -0.2 to 1.8 | 2,968 | NCT01424150 REstrictive Versus LIbEral Fluid Therapy in Major Abdominal Surgery: RELIEF Study |
| Liberal vs Restrictive: Pneumonia | 54 of 1,481 57 of 1,487 | -0.2 points -1.6 to 1.2 | 2,968 | NCT01424150 REstrictive Versus LIbEral Fluid Therapy in Major Abdominal Surgery: RELIEF Study |
| Liberal vs Restrictive: Anastomotic Leak | 35 of 1,487 49 of 1,481 | -1.0 points -2.2 to 0.2 | 2,968 | NCT01424150 REstrictive Versus LIbEral Fluid Therapy in Major Abdominal Surgery: RELIEF Study |
| Liberal vs Restrictive: Surgical Site Infection | 245 of 1,481 202 of 1,487 | 3.0 points 0.4 to 5.5 | 2,968 | NCT01424150 REstrictive Versus LIbEral Fluid Therapy in Major Abdominal Surgery: RELIEF Study |
| Daprodustat vs rhEPO: deaths from any cause | 294 of 1,487 300 of 1,477 | -0.5 points -3.4 to 2.3 | 2,964 | NCT02879305 Anemia Studies in Chronic Kidney Disease: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor Daprodustat-Dialysis (ASCEND-D) |
| High-Dose Vaccine for Residents vs Standard-dose for Residents: deaths from any cause | 249 of 1,461 274 of 1,496 | -1.3 points -4.0 to 1.5 | 2,957 | NCT01720277 High Dose Influenza Vaccine in Nursing Home - Pilot Study |
| HD Fluzone Vaccine vs SD Fluzone Vaccine: Change in Residents' Functional Status | 196 of 1,461 206 of 1,496 | -0.4 points -2.8 to 2.1 | 2,957 | NCT01720277 High Dose Influenza Vaccine in Nursing Home - Pilot Study |
| Daprodustat vs rhEPO: serious adverse events | 773 of 1,482 748 of 1,474 | 1.4 points -2.2 to 5.0 | 2,956 | NCT02879305 Anemia Studies in Chronic Kidney Disease: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor Daprodustat-Dialysis (ASCEND-D) |
| Intervention Group vs Control Group: Overweight | 385 of 1,641 683 of 1,309 | -28.7 points -32.1 to -25.3 | 2,950 | NCT00554294 Promoting Water Consumption for Prevention of Overweight in School Children in a Controlled Intervention Trial |
| Daprodustat vs rhEPO: Number of Participants With at Least One BP Exacerbation Event During Study | 1,191 of 1,480 1,186 of 1,470 | -0.2 points -3.1 to 2.6 | 2,950 | NCT02879305 Anemia Studies in Chronic Kidney Disease: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor Daprodustat-Dialysis (ASCEND-D) |
| Anastrozole vs Tamoxifen: Number of Breast Cancer Deaths | 3 of 1,449 3 of 1,489 | 0.0 points -0.4 to 0.4 | 2,938 | NCT00072462 Adjuvant Tamoxifen Compared With Anastrozole in Treating Postmenopausal Women With Ductal Carcinoma In Situ |
| Anastrozole vs Tamoxifen: Number of Participants With ER- Breast Cancer Recurrence | 24 of 1,449 15 of 1,489 | 0.6 points -0.2 to 1.5 | 2,938 | NCT00072462 Adjuvant Tamoxifen Compared With Anastrozole in Treating Postmenopausal Women With Ductal Carcinoma In Situ |
| Anastrozole vs Tamoxifen: Number of Participants With Breast Cancer Recurrence, Including Recurrent DCIS and New Contralateral Tumours | 103 of 1,449 120 of 1,489 | -1.0 points -2.9 to 1.0 | 2,938 | NCT00072462 Adjuvant Tamoxifen Compared With Anastrozole in Treating Postmenopausal Women With Ductal Carcinoma In Situ |
| Anastrozole vs Tamoxifen: Number of Participants With ER+ Breast Cancer Recurrence, Including Recurrent DCIS and New Contralateral Tumours | 58 of 1,449 82 of 1,489 | -1.5 points -3.1 to 0.0 | 2,938 | NCT00072462 Adjuvant Tamoxifen Compared With Anastrozole in Treating Postmenopausal Women With Ductal Carcinoma In Situ |
| Anastrozole vs Tamoxifen: Number of Non-breast Cancer Deaths | 59 of 1,449 65 of 1,489 | -0.3 points -1.8 to 1.2 | 2,938 | NCT00072462 Adjuvant Tamoxifen Compared With Anastrozole in Treating Postmenopausal Women With Ductal Carcinoma In Situ |
| Anastrozole vs Tamoxifen: deaths from any cause | 62 of 1,449 69 of 1,489 | -0.4 points -1.9 to 1.2 | 2,938 | NCT00072462 Adjuvant Tamoxifen Compared With Anastrozole in Treating Postmenopausal Women With Ductal Carcinoma In Situ |
Code
curl "https://conductscience.org/api/comparisons/v1?page=129"
Response
The first 2 of this page's 20 results. GET /api/comparisons/v1?page=129
{
"data": {
"total": 85013,
"results": [
{
"id": "NCT02073162-sae",
"title": "Liberal Group vs Restrictive Group: serious adverse events",
"summary": "103 of 1493 against 118 of 1490; risk difference -1.0 points, 95% interval -2.9 to 0.9; NCT02073162, REstrictive Versus LIbEral Fluid Therapy in Major Abdominal Surgery",
"record": "/library/comparisons/NCT02073162-sae",
"nct_id": "NCT02073162",
"kind": "serious-adverse-events",
"participants": 2983,
"risk_difference": {
"value": -0.010206017342677468,
"lower": -0.029136665387459806,
"upper": 0.008660030732024891
},
"group_1": "103 of 1,493",
"group_2": "118 of 1,490",
"difference": "-1.0 points",
"interval": "-2.9 to 0.9",
"trial_title": "REstrictive Versus LIbEral Fluid Therapy in Major Abdominal Surgery"
},
{
"id": "NCT00095576-sae",
"title": "Trivalent MRKAd5 HIV-1 Gag/Pol/Nef vs Placebo: serious adverse events",
"summary": "19 of 1484 against 17 of 1495; risk difference 0.1 points, 95% interval -0.7 to 1.0; NCT00095576, Investigation of V520 in an HIV Vaccine Proof-of-Concept Study (V520-023)",
"record": "/library/comparisons/NCT00095576-sae",
"nct_id": "NCT00095576",
"kind": "serious-adverse-events",
"participants": 2979,
"risk_difference": {
"value": 0.001431997043153728,
"lower": -0.006743378297861383,
"upper": 0.009717992960848548
},
"group_1": "19 of 1,484",
"group_2": "17 of 1,495",
"difference": "0.1 points",
"interval": "-0.7 to 1.0",
"trial_title": "Investigation of V520 in an HIV Vaccine Proof-of-Concept Study (V520-023)"
}
],
"no_events": 33758,
"columns": [
{
"key": "title",
"label": "Comparison"
},
{
"key": "group_1",
"label": "With the outcome",
"under": "group_2"
},
{
"key": "difference",
"label": "Risk difference, 95% interval",
"under": "interval"
},
{
"key": "participants",
"label": "Participants"
},
{
"key": "nct_id",
"label": "Trial",
"under": "trial_title"
}
],
"order": "Most participants first",
"kinds": {
"all": 85013,
"outcome": 33568,
"serious-adverse-events": 31897,
"deaths": 19548
}
},
"release": "trial-comparisons-2026-03-23-0.1.0",
"terms": [
{
"source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
"license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "Freely available. Acknowledgement requested"
},
{
"source": "ClinicalTrials.gov",
"license": "none stated",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "No license stated"
}
],
"next": "/api/comparisons/v1?page=130",
"request_id": "rOlIJvVH5lyweo1k"
}Ask about these results. The first 10 go in the prompt.
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
ClinicalTrials.gov
Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.
Patent publications
Paste a sequence and see the patents that disclose it.
Opens sequences.conductscience.org
For software
Every answer on this page is also JSON, under /api/comparisons/v1. No key.
GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome
Ask an assistant